BridgeBio Pharma spins out cancer-focused unit with three drugs, $200 million

The move should allow BridgeBio Pharma to concentrate on its heart failure drug, which could win FDA approval in November, as the spinout's cancer drugs enter clinical trials.

Source: bizjournals.com Health Care:Biotechnology headlines - May 2, 2024 Category: Biotechnology Authors: Ron Leuty Source Type: news